Effectiveness and Persistence with Liraglutide Among Patients with Type 2 Diabetes in Routine Clinical Practice—EVIDENCE: A Prospective, 2-Year Follow-Up, Observational, Post-Marketing Study

Advances in Therapy

Volumn 32, Issue 9, 2015, Pages 838-853

  Gautier, Jean Francois ^a   Martinez, Luc ^b   Penfornis, Alfred ^c   Eschwège, Eveline ^d   Charpentier, Guillaume ^c   Huret, Benoît ^e   Madani, Suliya ^e   Gourdy, Pierre ^f  

^a SAINT LOUIS HOSPITAL   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c CENTRE HOSPITALIER SUD FRANCILIEN   (France)

^d INSERM   (France)

^e NOVO NORDISK A S   (Denmark)

^f CHU RANGUEIL   (France)

Author keywords

BMI; Liraglutide; Observational; Type 2 diabetes; Weight

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; BIGUANIDE DERIVATIVE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLITAZONE DERIVATIVE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; LIRAGLUTIDE; SULFONYLUREA DERIVATIVE; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE 1; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN;

ABDOMINAL PAIN; ADULT; ARTICLE; ASTHENIA; ATRIAL FIBRILLATION; BODY MASS; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL PRACTICE; CONSTIPATION; CONSULTATION; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; DIABETIC PATIENT; DIARRHEA; DIGESTIVE SYSTEM FUNCTION DISORDER; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSPEPSIA; FEMALE; FLATULENCE; FOLLOW UP; GASTROESOPHAGEAL REFLUX; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART ARRHYTHMIA; HEART INFARCTION; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; KIDNEY CANCER; LOADING DRUG DOSE; LOSS OF APPETITE; LOW DRUG DOSE; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; METABOLIC DISORDER; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NUTRITIONAL DISORDER; OBSERVATIONAL STUDY; PATIENT; PATIENT COMPLIANCE; PATIENT SATISFACTION; PRESCRIPTION; PROSPECTIVE STUDY; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; SQUAMOUS CELL CARCINOMA; UPPER ABDOMINAL PAIN; VOMITING; WEIGHT CHANGE; WEIGHT CONTROL; AGED; BODY WEIGHT; CHEMICALLY INDUCED; DIABETES MELLITUS, TYPE 2; METABOLISM; MIDDLE AGED; POSTMARKETING SURVEILLANCE;

AGED; BLOOD GLUCOSE; BODY MASS INDEX; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; LIRAGLUTIDE; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PRODUCT SURVEILLANCE, POSTMARKETING; PROSPECTIVE STUDIES;

EID: 84944074514     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-015-0245-x     Document Type: Article

References (40)

1. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia. 2015;58:429–42.
2. Marre M, Shaw J, Brandle M, et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in patients with type 2 diabetes (LEAD-1 SU). Diabet Med. 2009;26:268–78.
3. Zinman B, Gerich J, Buse JB, et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met + TZD). Diabetes Care. 2009;32:1224–30.
4. Nauck M, Frid A, Hermansen K, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care. 2009;32:84–90.
5. Buse JB, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009;374:39–47.
6. Garber A, Henry R, Ratner R, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 mono): a randomised, 52-week, phase III, double-blind, parallel treatment trial. Lancet. 2008;373:473–81.
7. Russell-Jones D, Vaag A, Schmitz O, et al. Liraglutide vs. insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met + SU): a randomised controlled trial. Diabetologia. 2009;52:2046–55.
8. Croom KF, McCormack PL. Liraglutide: a review of its use in type 2 diabetes mellitus. Drugs. 2009;69:1985–2004.
9. Thong KY, Walton C, Ryder REJ. Safety and efficacy of liraglutide 1.2 mg in patients with mild and moderate renal impairment: the ABCD nationwide liraglutide audit. Pract Diabetes. 2013;30:71–6.
10. Thong KY, Gupta PS, Cull ML, et al. GLP-1 receptor agonists in type 2 diabetes—NICE guidelines versus clinical practice. Br J Diabetes Vasc Dis. 2014;14:52–9.
11. Lee WC, Dekoven M, Bouchard J, Massoudi M, Langer J. Improved real-world glycaemic outcomes with liraglutide versus other incretin-based therapies in type 2 diabetes. Diabetes Obes Metab. 2014;16:819–26.
12. Novo Nordisk. Liraglutide SmPC. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001026/WC500050017.pdf. Accessed 29 June 2015.
13. Marre M, Pinget M, Gin H, et al. Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain: 52-week data from the PREDICTIVE study in a cohort of French patients with type 1 or type 2 diabetes. Diabetes Metab. 2009;35:469–75.
14. Niswender K, Pi-Sunyer X, Buse J, et al. Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme. Diabetes Obes Metab. 2013;15:42–54.
15. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32:193–203.
16. Nyeland ME, Ploug UJ, Richards A, et al. Evaluation of the effectiveness of liraglutide and sitagliptin in type 2 diabetes: a retrospective study in UK primary care. Int J Clin Pract. 2015;69:281–91.
17. ®)) in type 2 diabetic patients. Diabetes Metab Syndr. 2015;9:139–42.
18. Mezquita-Raya P, Reyes-Garcia R, Moreno-Perez O, Escalada-San Martin J, Herrera MÁR. Clinical effects of liraglutide in a real-world setting in Spain: eDiabetes-Monitor SEEN Diabetes Mellitus Working Group Study. Diabetes Ther 2015 6:173–85.
19. Garber A, Henry RR, Ratner R, et al. Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes. Diabetes Obes Metab. 2011;13:348–56.
20. Hall GC, McMahon AD, Dain MP, Wang E, Home PD. Primary-care observational database study of the efficacy of GLP-1 receptor agonists and insulin in the UK. Diabet Med. 2013;30:681–6.
21. Shyangdan DS, Royle PL, Clar C, Sharma P, Waugh N, Snaith A. Glucagon-like peptide analogues for type 2 diabetes mellitus: systematic review and meta-analysis. BMC Endocr Disord. 2010;9:10–20.
22. Vilsbøll T, Christensen M, Junker AE, Knop FK, Gluud LL. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ. 2012;344:d7771.
23. Pratley RE, Nauck MA, Bailey T, et al. Efficacy and safety of switching from the DPP-4 inhibitor sitagliptin to the human GLP-1 analog liraglutide after 52 weeks in metformin-treated patients with type 2 diabetes: a randomized, open-label trial. Diabetes Care. 2012;35:1986–93.
24. Violante R, Oliveira JH, Yoon KH, et al. A randomized non-inferiority study comparing the addition of exenatide twice daily to sitagliptin or switching from sitagliptin to exenatide twice daily in patients with type 2 diabetes experiencing inadequate glycaemic control on metformin and sitagliptin. Diabet Med. 2012;29:e417–24.
25. Hazell L, Shakir SA. Under-reporting of adverse drug reactions: a systematic review. Drug Saf. 2006;29:385–96.
26. Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology. 2011;141:150–6.
27. Singh S, Chang HY, Richards TM, Weiner JP, Clark JM, Segal JB. Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case–control study. JAMA Intern Med. 2013;173:534–9.
28. Matveyenko AV, Dry S, Cox HI, et al. Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: interactions with metformin. Diabetes. 2009;58:1604–15.
29. Nachnani JS, Bulchandani DG, Nookala A, et al. Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas. Diabetologia. 2010;53:153–9.
30. Gier B, Matveyenko AV, Kirakossian D, Dawson D, Dry SM, Butler PC. Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the Kras(G12D) mouse model. Diabetes. 2012;61:1250–62.
31. Gale EA. GLP-1 based agents and acute pancreatitis: drug safety falls victim to the three monkey paradigm. BMJ. 2013;346:f1263.
32. Gier B, Butler PC. Glucagonlike peptide 1-based drugs and pancreatitis: clarity at last, but what about pancreatic cancer? JAMA Intern Med. 2013;173:539–41.
33. Jensen TM, Saha K, Steinberg WM. Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials. Diabetes Care. 2015;38:1058–66.
34. Noel RA, Braun DK, Patterson RE, Bloomgren GL. Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study. Diabetes Care. 2009;32:834–8.
35. Thomsen RW, Pedersen L, Møller N, Kahlert J, Beck-Nielsen H, Sørensen HT. Incretin-based therapy and risk of acute pancreatitis: a nationwide population-based case–control study. Diabetes Care. 2015. doi:10.2337/dc13-2983.
36. Faillie JL, Babai S, Crépin S, et al. Pancreatitis associated with the use of GLP-1 analogs and DPP-4 inhibitors: a case/non-case study from the French Pharmacovigilance Database. Acta Diabetol. 2014;51:491–7.
37. Egan AG, Blind E, Dunder K, et al. Pancreatic safety of incretin-based drugs—FDA and EMA assessment. N Engl J Med. 2014;370:794–7.
38. Hendrychova T, Vytrisalova M, Smahelova A, Vlcek J, Kubena AA. Adherence in adults with type 1 diabetes mellitus correlates with treatment satisfaction but not with adverse events. Patient Prefer Adherence. 2013;7:867–76.
39. Ken W, Koopmanschap MA, Stolk RP, Rutten GE, Wolffenbuttel BH, Niessen LW. Health-related quality of life and treatment satisfaction in Dutch patients with type 2 diabetes. Diabetes Care. 2002;25:458–63.
40. Bradley C, Lewis KS. Measures of psychological well-being and treatment satisfaction developed from the responses of people with tablet-treated diabetes. Diabet Med. 1990;7:445–51.